Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCELERON PHARMA INCXLRN · Entity 15780 | EVP & Chief Medical Officer | April 03, 2018 | April 04, 2018 |
| LUMOS PHARMA, INC.(NLNK) · Entity 85102 | Director | July 31, 2019 | August 02, 2019 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | June 21, 2023 | June 23, 2023 |
| Pulmatrix, Inc.PULM · Entity 8249 | Director | May 16, 2019 | May 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCELERON PHARMA INC
Report date April 03, 2018 · Filed April 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,767 |
Ending reported balance
After 2018-04-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-03 · Sale · Disposed 3,700 · Balance 69,667 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Row 2 · 2018-04-03 · Sale · Disposed 900 · Balance 68,767 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Irrevocable Trust | 8,500 |
Reported balance
Holding disclosure · report date 2018-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
LUMOS PHARMA, INC.
Report date July 31, 2019 · Filed August 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2028-04-29 | Direct | 0 |
Reported balance
After 2019-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-31 · Disposition to issuer · Disposed 63,447 · Balance 0 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2026-07-31 | Direct | 13,218 |
Reported balance
After 2019-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-31 · Grant · Acquired 13,218 · Balance 13,218 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2026-07-31 | Direct | 18,506 |
Reported balance
After 2019-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-31 · Grant · Acquired 18,506 · Balance 18,506 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F3: The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2028-05-22 | Direct | 0 |
Reported balance
After 2019-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-31 · Disposition to issuer · Disposed 27,777 · Balance 0 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F4: The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2026-07-31 | Direct | 13,889 |
Reported balance
After 2019-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-31 · Grant · Acquired 13,889 · Balance 13,889 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
F2: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
F3: The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.
F4: The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date.
PALVELLA THERAPEUTICS, INC.
Report date June 21, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2033-06-21 | Direct | 40,000 |
Reported balance
After 2023-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-21 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date.
Pulmatrix, Inc.
Report date May 16, 2019 · Filed May 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-05-16 | Direct | 15,000 |
Reported balance
After 2019-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-16 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 11, 2024
Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 144,290 |
Reported balance
After 2024-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 34,157 · Balance 144,290 F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. F2: Includes 1,394 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 72,261 |
Reported balance
After 2024-06-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-06-11 · Disposition to issuer · Disposed 72,029 · Balance 72,261 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-06-11 · Other · Disposed 72,261 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 82,265 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-11 · Disposition to issuer · Disposed 82,000 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-11 · Disposition to issuer · Disposed 65,900 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.92 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-06-11 · Disposition to issuer · Disposed 69,100 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred.
F2: Includes 1,394 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2024.
F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding.
F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2024 Filed Jun 11, 2024 21:02 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 69,100 | Not disclosed Strike: $15.92 | Not disclosed |
DisclosureSEC source: 0000950170-24-072223 · ownership.xml · derivative · entry 7 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,100 shares Expires not disclosed F3 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:02 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 65,900 | Not disclosed Strike: $15.48 | Not disclosed |
DisclosureSEC source: 0000950170-24-072223 · ownership.xml · derivative · entry 6 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,900 shares Expires not disclosed F3 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:02 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 82,000 | Not disclosed Strike: $8.27 | Not disclosed |
DisclosureSEC source: 0000950170-24-072223 · ownership.xml · derivative · entry 5 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,000 shares Expires not disclosed F3 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:02 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 82,265 | Not disclosed Strike: $9.23 | Not disclosed |
DisclosureSEC source: 0000950170-24-072223 · ownership.xml · derivative · entry 4 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,265 shares Expires not disclosed F3 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:02 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | OtherCommon Stock | 72,261 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-072223 · ownership.xml · nonDerivative · entry 3 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:02 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerCommon Stock | 72,029 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-072223 · ownership.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,261 F3 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:02 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | GrantCommon Stock | 34,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-072223 · ownership.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,290 F1 · kind: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. F1 · price: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. F2 · balance_after: Includes 1,394 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2024. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 16:06 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,615 | $15.62 | $40,840.29 |
DisclosureSEC source: 0000950170-24-017085 · ownership.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,739 F2 · kind: This sale was to cover tax liabilities in the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6172 to $15.6177, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 16:06 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 69,100 | $0.00 Strike: $15.92 | $0.00 |
DisclosureSEC source: 0000950170-24-017085 · ownership.xml · derivative · entry 3 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,100 Underlying: Common Stock · 69,100 shares Expires 2034-02-14 F4 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 16:06 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 17,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-017085 · ownership.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,354 F1 · kind: The reporting person was awarded 17,275 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,435 | $14.47 | $35,233.72 |
DisclosureSEC source: 0000950170-24-005393 · ownership.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,079 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock units. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,792 | $15.37 | $42,904.94 |
DisclosureSEC source: 0000950170-23-070382 · ownership.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,514 F3 · kind: This sale was to cover tax liabilities in the vesting of RSUs. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 8,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-070382 · ownership.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,306 F1 · kind: On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs. F1 · price: On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs. F2 · balance_after: Includes 434 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023. Read SEC document |
| October 30, 2023 Filed Oct 31, 2023 16:11 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,360 | $12.02 | $28,361.54 |
DisclosureSEC source: 0001209191-23-053939 · doc4.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,628 F2 · kind: This sale was to cover tax liabilities in the vesting of RSUs. Read SEC document |
| October 28, 2023 Filed Oct 31, 2023 16:11 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 8,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-053939 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,988 F1 · kind: On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 8,244 RSUs. F1 · price: On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 8,244 RSUs. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,942 | $12.68 | $37,304.56 |
DisclosureSEC source: 0001209191-23-051886 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,744 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock units. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:45 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001437749-23-018278 · rdgdoc.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 1,655 | $14.40 | $23,834.98 |
DisclosureSEC source: 0001209191-23-038756 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,686 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock units. F2 · balance_after: Includes 1,196 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 16:07 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 971 | $15.10 | $14,661.13 |
DisclosureSEC source: 0001209191-23-010506 · doc4.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,145 F2 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:07 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 65,900 | $0.00 Strike: $15.48 | $0.00 |
DisclosureSEC source: 0001209191-23-010506 · doc4.xml · derivative · entry 3 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,900 Underlying: Common Stock · 65,900 shares Expires 2033-02-14 F3 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:07 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 16,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010506 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,116 F1 · kind: The reporting person was awarded 16,488 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,403 | $21.24 | $51,042.84 |
DisclosureSEC source: 0001209191-23-003998 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,628 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. F2 · balance_after: Includes 734 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2022. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,587 | $18.73 | $48,454.51 |
DisclosureSEC source: 0001209191-22-052717 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,297 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 19:02 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001583648-22-000048 · wf-form4_165611172543156.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2023 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:37 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 1,768 | $10.75 | $19,006.00 |
DisclosureSEC source: 0001209191-22-038432 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,884 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. F2 · balance_after: Includes 1,862 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2022. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 17:01 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 984 | $9.05 | $8,905.20 |
DisclosureSEC source: 0001209191-22-011361 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,790 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 82,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0001209191-22-004076 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2032-01-17 F2 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004076 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,774 F1 · kind: The reporting person was awarded 20,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs shall vest in three (3) equal annual installments on each of January 15, 2023, January 15, 2024 and January 15, 2025. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 82,265 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001209191-21-070232 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,265 Underlying: Common Stock · 82,265 shares Expires 2031-12-14 F3 · derivative.exercise_date: This stock option was issued pursuant to the 2017 Plan. The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 11,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070232 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,274 F1 · kind: The reporting person was awarded 11,100 Restricted Stock Units ("RSUs") under the Issuer's 2017 Stock Option and Incentive Plan (the "2017 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through such dates. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. F2 · balance_after: Includes 145 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 12, 2021. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 16:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,659 | $33.17 | $88,199.03 |
DisclosureSEC source: 0001209191-21-059804 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,029 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. F2 · balance_after: Includes 302 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2021. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 17:38 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004564 · primarydocument.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2022 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 19:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 49,900 | $0.00 Strike: $47.79 | $0.00 |
DisclosureSEC source: 0001209191-21-012114 · doc4.xml · derivative · entry 3 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,900 Underlying: Common Stock · 49,900 shares Expires 2031-02-15 F3 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 19:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 11,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012114 · doc4.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,386 F2 · kind: The reporting person was awarded 11,100 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2022, February 15, 2023, February 15, 2024 and February 15, 2025, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 19:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 132 | $48.87 | $6,450.84 |
DisclosureSEC source: 0001209191-21-012114 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,286 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 16:10 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to buy) · Derivative | 207 | $0.00 Strike: $34.43 | $0.00 |
DisclosureSEC source: 0001209191-20-062920 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,096 Underlying: Common Stock · 207 shares Expires 2029-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on October 1, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 16:10 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 207 | $34.43 | $7,127.01 |
DisclosureSEC source: 0001209191-20-062920 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:31 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to buy) · Derivative | 2,697 | $0.00 Strike: $34.43 | $0.00 |
DisclosureSEC source: 0001209191-20-059256 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,303 Underlying: Common Stock · 2,697 shares Expires 2029-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on October 1, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:31 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 2,697 | $34.43 | $92,857.71 |
DisclosureSEC source: 0001209191-20-059256 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 386 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2020. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 16:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Tax withholdingCommon Stock | 2,632 | $51.15 | $134,618.11 |
DisclosureSEC source: 0001209191-20-053994 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,128 F1 · kind: This sale was to cover tax liabilities in the vesting of restricted stock. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 16:46 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001562180-20-004692 · primarydocument.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on June 23, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 16:10 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 10,520 | $0.00 Strike: $54.87 | $0.00 |
DisclosureSEC source: 0001209191-20-011041 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,520 Underlying: Common Stock · 10,520 shares Expires 2030-02-17 F2 · derivative.exercise_date: This stock option award was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 16:10 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 1,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011041 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,760 F1 · shares: The reporting person was awarded 1,760 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2021, February 15, 2022, February 15, 2023 and February 15, 2024, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 16:22 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001562180-20-000625 · primarydocument.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 16:35 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $34.43 | $0.00 |
DisclosureSEC source: 0001209191-19-053427 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-10-14 F2 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on October 1, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 16:35 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053427 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · kind: The reporting person was awarded 35,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in four (4) equal annual installments beginning on October 1, 2020, subject to the reporting person's continuous service with the Company through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 18:39 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 13,889 | Not disclosed Strike: $1.77 | Not disclosed |
DisclosureSEC source: 0001126234-19-000106 · wf-form4_156478558165297.xml · derivative · entry 5 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,889 Underlying: Common Stock · 13,889 shares Expires 2026-07-31 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2 · derivative.exercise_date: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 18:39 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 27,777 | Not disclosed Strike: $5.33 | Not disclosed |
DisclosureSEC source: 0001126234-19-000106 · wf-form4_156478558165297.xml · derivative · entry 4 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,777 shares Expires 2028-05-22 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F4 · derivative.exercise_date: The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 18:39 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 18,506 | Not disclosed Strike: $1.77 | Not disclosed |
DisclosureSEC source: 0001126234-19-000106 · wf-form4_156478558165297.xml · derivative · entry 3 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,506 Underlying: Common Stock · 18,506 shares Expires 2026-07-31 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F3 · derivative.exercise_date: The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 18:39 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 13,218 | Not disclosed Strike: $1.77 | Not disclosed |
DisclosureSEC source: 0001126234-19-000106 · wf-form4_156478558165297.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,218 Underlying: Common Stock · 13,218 shares Expires 2026-07-31 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2 · derivative.exercise_date: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.